{"symbol":"AMGN","fiscalQuarter":"Q3-2022","reportDate":"2022-11-03","reportTime":"AMC","status":"reported","company":{"name":"Amgen Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/AMGN/earnings/Q3-2022","postBrief":{"headline":"Amgen Beats on EPS, Stock Down 1.16%","keyNumbers":[{"metric":"EPS","actual":"$4.70","expected":"N/A","surprise":"+6.17%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key therapeutic areas.","They acknowledged ongoing challenges in the market but expressed confidence in their pipeline.","The team emphasized their commitment to innovation and patient access."],"summary":"Overall, management conveyed a sense of cautious optimism about future growth. They pointed to strong product performance while recognizing market challenges."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Amgen's earnings report showed a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by 1.16%, likely due to the lack of revenue data and guidance, which may have left investors uncertain about future performance. The cautious tone from management may have also contributed to the stock's decline.","metaDescription":"Amgen Inc (AMGN) Q3 2022 earnings: EPS beat by 6.17%. Stock down 1.16%. Full breakdown."}}